Sparks commentary

Healthcare

Sparks

FDA approves Soleno Therapeutics’ (Nasdaq: SLN) Vykat XR
Published by Arron Aatkar, PhD

The US FDA has today approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets. This marks the first FDA approved treatment to address hyperphagia in Prader-Willi syndrome, a rare neurodevelopmental condition (caused by a genetic abnormality) estimated to afflict one in every 15,000 babies in the US each year.

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO